Search research articles
Contact Us
Filters
Showing results (1-10 of 417) with videos related to
Page
of 42
Sort By:
Clinical Advances in Hematology & Oncology : H&O
|
December 29, 2025
What is the role of asciminib in chronic myeloid leukemia?
Jorge E Cortes
Future Oncology (London, England)
|
May 31, 2013
A journey searching for a cure for leukemia. Interviewed by Natasha Galukande
Jorge E Cortes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2011
Not only response but early response to tyrosine kinase inhibitors in chronic myeloid leukemia
Jorge E Cortes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2008
Imatinib therapy for chronic myeloid leukemia: where do we go now?
Jorge E Cortes
Blood Advances
|
December 28, 2018
A second-generation TKI should always be used as initial therapy for CML
Jorge E Cortes
Expert Review of Hematology
|
May 15, 2024
Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia
Jorge E Cortes
American Journal of Hematology
|
December 28, 2020
Determination of fitness and therapeutic options in older patients with acute myeloid leukemia
Jorge E Cortes, Priyanka Mehta
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 14, 2017
Reply to K.R. Hoffman
Jorge E Cortes, Andreas Hochhaus
International Journal of Hematology
|
July 9, 2004
Imatinib mesylate in the treatment of chronic myelogenous leukemia
Gautam Borthakur, Jorge E Cortes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 9, 2014
Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia
Hagop Kantarjian, Jorge E Cortes
Page
of 42
Search research articles
Search
Showing results (1-10 of 417) with videos related to
Sort By:
Page
of 42
Clinical Advances in Hematology & Oncology : H&O
|
December 29, 2025
What is the role of asciminib in chronic myeloid leukemia?
Jorge E Cortes
Future Oncology (London, England)
|
May 31, 2013
A journey searching for a cure for leukemia. Interviewed by Natasha Galukande
Jorge E Cortes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2011
Not only response but early response to tyrosine kinase inhibitors in chronic myeloid leukemia
Jorge E Cortes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2008
Imatinib therapy for chronic myeloid leukemia: where do we go now?
Jorge E Cortes
Blood Advances
|
December 28, 2018
A second-generation TKI should always be used as initial therapy for CML
Jorge E Cortes
Expert Review of Hematology
|
May 15, 2024
Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia
Jorge E Cortes
American Journal of Hematology
|
December 28, 2020
Determination of fitness and therapeutic options in older patients with acute myeloid leukemia
Jorge E Cortes, Priyanka Mehta
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 14, 2017
Reply to K.R. Hoffman
Jorge E Cortes, Andreas Hochhaus
International Journal of Hematology
|
July 9, 2004
Imatinib mesylate in the treatment of chronic myelogenous leukemia
Gautam Borthakur, Jorge E Cortes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 9, 2014
Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia
Hagop Kantarjian, Jorge E Cortes
Page
of 42